Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine
Balraj Singh(The University of Texas MD Anderson Cancer Center), Anthony Lucci(The University of Texas MD Anderson Cancer Center)
Cited by 18
Related Papers
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge
|PLoS ONE|2016|137
Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential
|Oncotarget|2019|12